TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01987349

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® (intramuscular)
Description: Licensed seasonal trivalent inactivated influenza vaccine (IIV3)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® (intramuscular)
Description: Licensed seasonal trivalent inactivated influenza vaccine (IIV3)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® (intramuscular)
Description: Licensed seasonal trivalent inactivated influenza vaccine (IIV3)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist® (intranasal)
Description: Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist® (intranasal)
Description: Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist® (intranasal)
Description: Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist® (intranasal)
Description: Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist® (intranasal)
Description: Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)
Study: NCT00862316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxford Unicompartmental Knee
Description: Knee Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxford Unicompartmental Knee
Description: Knee Arthroplasty
Study: NCT03993964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib combine with SHR6390
Description: SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic breast cancer
Study: NCT00264602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Near Infrared Imaging
Description: Dye injected into or around tumor at the time of surgery
Study: NCT04254783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytochrome P450 (CYP) Substrates
Description: Tablet: Oral; CYP Substrates: midazolam, caffeine, warfarin, vitamin K, omeprazole and metoprolol
Study: NCT02332213

Intervention type: PROCEDURE
Intervention: Breath sampling for volatile marker detection
Description: Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology

Intervention type: PROCEDURE
Intervention: Breath sampling for volatile marker detection
Description: Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology

Intervention type: PROCEDURE
Intervention: Breath sampling for volatile marker detection
Description: Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology

Intervention type: PROCEDURE
Intervention: Breath sampling for volatile marker detection
Description: Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology

Intervention type: PROCEDURE
Intervention: Upper endoscopy with biopsies
Description: Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing

Intervention type: PROCEDURE
Intervention: Upper endoscopy with biopsies
Description: Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing

Intervention type: PROCEDURE
Intervention: Upper endoscopy with biopsies
Description: Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing

Intervention type: PROCEDURE
Intervention: Upper endoscopy with biopsies
Description: Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing

Intervention type: PROCEDURE
Intervention: Colonoscopy with biopsies or lesion removal when required
Description: Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing

Intervention type: PROCEDURE
Intervention: Colonoscopy with biopsies or lesion removal when required
Description: Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
Study: NCT03445897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miltefosine plus intralesional pentamidine
Description: miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
Study: NCT01755468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent insulin therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous metformin
Study: NCT01757613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AK 3012
Description: cutaneous use twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AK 3012
Description: cutaneous use twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AK 3012
Description: cutaneous use twice a day
Study: NCT04019275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENGAGE
Description: ENGAGE blends social learning, guided discovery and skill training focused on community participation
Study: NCT01368159

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Compression Stockings
Description: The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Stockings
Description: The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Stockings
Description: The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied.
Study: NCT01897922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An investigational infant formula containing a probiotic source

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Marketed routine infant formula
Study: NCT01021605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemolung Respiratory Assist System
Description: Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive or invasive ventilation and then the Hemolung RAS. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
Study: NCT03218982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced psycho-education about dementia and caregiving
Description: Enhanced psycho-education re dementia and caregiving helping family members come to shared understanding of the nature and cause of dementia. Discussion of cultural values in Vietnamese and American cultures and how this can influence perceptions of dementia and caregiving strategies will help family members who disagree on the etiology of dementia and strategies for care to empathize with each other's perspective. Other sessions will teach skills to develop self-efficacy in dealing with patient symptoms, to access resources (e.g., in-home support), and to gain family support in culturally-congruent ways. Mindful Tai Chi is rooted in East Asian traditions and philosophies that promote balance and healing of the mind and body, thus addressing holistic beliefs Vietnamese have about wellness.
Study: NCT01449552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: the drain was not clamped and the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drain clamping
Description: the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drain clamping and tranexamic acid
Description: the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No clamp and placebo
Description: The drain was not clamped. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
Study: NCT02294409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manualized group Cognitive-behavioral therapy (CBT) for social anxiety in first episode psychosis
Description: All CBT sessions will be conducted in English or French by trained clinicians with the aid of a group CBT script that we have developed over the last two years. The script will provide a general outline for each session, remind the therapist about relevant CBT principles, and provide examples of topics and homework that may be useful in each session. This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring; iii) Exposure component; iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia. The latter module specifically examines stigmatization and self-stigmatization that are contributing factors to social anxiety. Each of the 13 group sessions consisting of 6-8 participants on average, will last for 1.5 hour each. One session per week will be provided for the 13-week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Computer assisted cognitive remediation therapy
Description: This group intervention has been developed by Dr. Bowie a co-applicant on the current proposal. This intervention involves completing cognitive training activities on a computer, documenting and attempting new strategies for solving problems, and doing 'bridging activities'. The target domains of cognition to be trained are processing speed, attention, memory and executive functions. The investigators will perform 13 weekly sessions of 1.5 hours. The software Brain Training Pro (http://www.scientificbraintrainingpro.fr), which has been used extensively in the field of schizophrenia, will be used. Each 1.5 hour session will be conducted with groups of 6-8 participants. The therapist's interventions, while minimal, are meant to emphasize the link between activities in the CACRT sessions and day-to-day activities that people do.
Study: NCT03419052

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speed of processing training
Description: Speed of processing training is provided by the Internet-based BrainHQ program from Posit Science, Inc. BrainHQ contains five different speed training modules (Hawk Eye, Visual Sweeps, Fine Tuning, Eye for Detail, Sound Sweeps) which tap time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of processing training
Description: Speed of processing training is provided by the Internet-based BrainHQ program from Posit Science, Inc. BrainHQ contains five different speed training modules (Hawk Eye, Visual Sweeps, Fine Tuning, Eye for Detail, Sound Sweeps) which tap time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MIND foods
Description: The MIND diet (created by the Rush Aging \& Memory group) specifically emphasizes foods high in polyphenols such as berries, nuts, cocoa, black beans, olive oil, and green leafy vegetables. Participants select these foods from the digital study application and receive them through home delivery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND foods
Description: The MIND diet (created by the Rush Aging \& Memory group) specifically emphasizes foods high in polyphenols such as berries, nuts, cocoa, black beans, olive oil, and green leafy vegetables. Participants select these foods from the digital study application and receive them through home delivery.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive training control
Description: Control training is provided by the Internet-based BrainHQ program from Posit Science, Inc.These are inert games such as tic-tac-toe, connect 4, battleship, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training control
Description: Control training is provided by the Internet-based BrainHQ program from Posit Science, Inc.These are inert games such as tic-tac-toe, connect 4, battleship, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control foods
Description: Foods contain low polyphenols. Participants select these foods from the digital study application and receive them through home delivery.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control foods
Description: Foods contain low polyphenols. Participants select these foods from the digital study application and receive them through home delivery.
Study: NCT04941352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-session Interpersonal Relations Theory-based Motivational Interviews and 3 month follow-up.
Description: 6-session Interpersonal Relations Theory-based Motivational Interviews were applied to the individuals in the study group. All sessions were conducted face-to-face in the form of individual interviews. Each interview lasted an average of 30-40 minutes. With this intervention, it was aimed to increase treatment cooperation and motivation in individuals with schizophrenia, to increase insight, to improve adherence to treatment, daily living skills and social functionality.Study data were collected using a personal information form, the Functional Remission of General Schizophrenia Scale (FROGS) and the Scale for Assessing the Three Components of Insight (SAI). The data were analyzed on the basis of pre-intervention, post-intervention and 3 months after the intervention.
Study: NCT03733873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: take desmopressin for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: take desmopressin for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suoquan
Description: take Suoquan mixture for 3 months
Study: NCT03335852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abicipar pegol
Description: Abicipar pegol 2 mg administered to the study eye by intravitreal injection
Study: NCT05692648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supine position group
Description: These neonates were placed in supine position, fed every 2 hours in accordance with routine clinical practice, and then returned to supine position.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hourly position change group
Description: Infants in this group were repositioned every hour based on the time of phototherapy initiation. Neonates were initially placed in supine position and then changed to the prone position. Infants were alternated between supine and prone positions every hour for 24 hours.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group (2-hour position change)
Description: Neonates in this group were repositioned every 2 hours as routine practice based on the time of phototherapy initiation. Phototherapy was started with neonates in supine position. In the second period, the neonate was placed in the prone position after routine feeding was performed.
Study: NCT01951235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin
Study: NCT02332213

Intervention type: PROCEDURE
Intervention: Colonoscopy with biopsies or lesion removal when required
Description: Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing

Intervention type: PROCEDURE
Intervention: Colonoscopy with biopsies or lesion removal when required
Description: Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing

Intervention type: PROCEDURE
Intervention: Plasma/serum sampling
Description: Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination

Intervention type: PROCEDURE
Intervention: Plasma/serum sampling
Description: Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination

Intervention type: PROCEDURE
Intervention: Plasma/serum sampling
Description: Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination

Intervention type: PROCEDURE
Intervention: Plasma/serum sampling
Description: Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
Study: NCT02632305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel in combination with gemcitabine + cisplatin
Description: Patients with unresectable BTC will be treated with the triple combination of nab-paclitaxel in combination with gemcitabine + cisplatin
Study: NCT03145480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6
Study: NCT00005830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT01951235

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04124536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV self-testing with partner notification.
Description: HIV self-test kits are oral swabs. Partner notification will be offered to all women in the intervention arm, regardless of HIV status.
Study: NCT00459485

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc sulfate
Description: 20 or 10 mg zinc per day for 3 weeks
Study: NCT02332213

Intervention type: PROCEDURE
Intervention: Plasma/serum sampling
Description: Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
Study: NCT00005830

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT04942847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sucking trainer
Description: Repeated sucking for tongue flexibility training can improve the tongue muscle's ability to control and transmit food, and improve the swallowing function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive card
Description: To measure the patient's ability to focus, to calculate, to remember and to judge
Study: NCT02996578

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: polyphenol rich chocolate bar
Description: High polyphenol content chocolate bar. Each participant will consume 581.4mg of polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: polyphenol rich cocoa powder
Description: High polyphenol content cocoa powder. Each participant will consume 6g containing 554mg of polyphenols
Study: NCT03145480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560mg po daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHOP
Description: cyclophosphamide, doxorubicin, vincristine, and prednisone
Study: NCT04706078

Intervention type: DIAGNOSTIC_TEST
Intervention: The biotype of gingival
Description: The biotype of gingival was also determined by periodontal probe.
Study: NCT02128607

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SNAG
Description: sustained natural apophyseal glide: SNAG / Mulligan technique

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Study: NCT00459485

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc sulfate
Description: 20 or 10 mg zinc per day for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo for 3 weeks